Study #2016-1107
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4c1032T in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Urinary Bladder Cancer;Melanoma;Head and Neck Cancer;Ovarian Cancer;Non-Small Cell Lung Cancer;Esophageal Cancer;Gastric Cancer;Synovial Sarcoma;Myxoid Round Cell Liposarcoma;Gastroesophageal Junction
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.